CID medication for dogs gets FDA renewalNovember 6, 2024Canalevia-CA1 (crofelemer delayed-release tablets) can be given orally twice a day and is used for home treatment of dogs suffering from chemotherapy-induced diarrhea (CID).
SPONSORED CONTENTYour Parasite Protection Recommendation, SimplifiedManaging parasite prevention doesn’t have to be complicated. Discover a single solution that protects against multiple threats. + Learn More
Broad canine oral parasiticide gets FDA approvalOctober 8, 2024The single monthly dose parasiticide is recommended to protect against six parasites, including fleas, ticks, heartworms, hookworms, and tapeworms.
Canine platelet-rich plasma injectable gets FDA clearanceApril 30, 2024The off-the-shelf product is intended to provide a canine-specific source of concentrated platelets in plasma for intra-articular administration in dogs.
Aratana Therapeutics' Nocita 10 ml gets FDA approvalJune 13, 2019Aratana Therapeutics announced the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) has approved an additional vial size (10 ml) of Nocita. "Since its launch in 2016, Nocita has drastically changed veterinary multimodal pain management protocols because it safely and effectively controls pain in patients for up to 72 hours following certain canine and feline surgeries," says Aratana Therapeutics chief development officer, Ernst Heinen, DVM, PhD. "Ultimately, we believe a smaller vial size may allow for expanded use and improve the level of care veterinarians provide for certain painful surgeries." Nocita, which is currently available in a 20-ml vial size, is a local postoperative analgesia for cranial cruciate ligament surgery in dogs and a peripheral nerve block following owner-elected onychectomy (declawing) in cats. The smaller vial size is expected to be made commercially available in fall 2019.
FDA approves treatment for urinary incontinence in dogsApril 2, 2019PROIN ER, a tablet for the control of urinary incontinence in dogs, has been approved by the U.S. Food and Drug Administration (FDA). The drug treats urethral sphincter hypotonus, which occurs due to a dog's age and weakening muscles in the urethra. PROIN Chewable Tablets have already been approved by the FDA; however, they are to be administered twice a day, whereas PROIN ER is a once-a-day extended-release formulation. The effectiveness of PROIN ER was observed in a clinical study comprising 119 dogs that had been previously diagnosed with urethral sphincter hypotonus and had been taking PROIN Chewable Tablets. The timeline of the clinical study went as follows: • For the first week, the owners documented whether the dog received the PROIN Chewable Tablet doses and noted the number of urinary accidents the dog had; • Dogs were then given PROIN ER for the first 28 days and the owners proceeded to take note of how many accidents occurred in a day; • In the fourth week, the number of urinary accidents was compared to the first week. It was found 75 of the 104 dogs who completed the study had no accidents on either tablet;
Injectable anesthetic Alfaxan Multidose approved by FDAJuly 17, 2018A new product registration of the intravenous injectable anesthetic Alfaxan has received approval by the FDA Center for Veterinary Medicine. Alfaxan Multidose contains the same formula as the original product, but with an added preservative to extend product shelf life to 28 days after the vial has been broached.
Aratana secures third FDA approvalAugust 16, 2016The future is much brighter at Aratana Therapeutics Inc. The Leawood, Kan., company this week won U.S. government approval of its third veterinary biopharmaceutical, Nocita (bupivacaine liposome injectable suspension).
